Navigation Links
NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/10/2008

tions, that the Company believes offers significant advantages over other pain therapies. NeurogesX submitted a new drug application (NDA) for NGX-4010 with the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which is subject to acceptance by the FDA. Additionally, a marketing authorization application (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the European Medicines Agency (EMEA).

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in Phase 1 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the potential markets for NeurogesX' product candidates; the expected benefits of NeurogesX' product candidates; and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European re
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Reports Third Quarter 2008 Results
2. NeurogesX to Report Third Quarter 2008 Financial Results
3. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
4. NeurogesX Responds to EMEAs Day 120 Questions
5. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
6. NeurogesX Reports Second Quarter 2008 Results
7. NeurogesX to Report Second Quarter 2008 Financial Results
8. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
9. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. NeurogesX Reports First Quarter 2008 Results
11. NeurogesX to Report First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... NES-ZIONA, Israel, Sept. 21 PROLOR Biotech, Inc. (OTC ... of a Phase I clinical trial of its long-acting human ... hGH-CTP is being developed to provide growth hormone deficient adults ... per week that are currently required with a once-weekly or ...
... prolonged courses of stable disease and excellent, ... cancer, , , QUEBEC CITY, Sept. ... AEZS ) ("the Company"), a global biopharmaceutical company focused ... a Phase 1 study of its orally-active tubulin and topoisomerase ...
... ... most reliable and secure professional solution to inventory Ultra-low Freezer and Liquid Nitrogen Tank ... ... 21, 2009 -- RURO Inc. today announced the release of FreezerPro 2010, Frozen ...
Cached Biology Technology:PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 2PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 3PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 4AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer 3RURO Inc. Today Announced the Release of FreezerPro 2010, Frozen Sample Inventory and Information Management System 2
(Date:4/22/2014)... 2014) -- There are all sorts of signaling strategies ... their colorful tails; satin bowbirds build specialized stick structures, ... objects; and European bitterling males show off bright nuptial ... unique method to communicate with others. , ... can have profound fitness implications for individuals that are ...
(Date:4/22/2014)... University of Montana,s Wildlife Biology Program, co-wrote a research paper ... Academy of Sciences on how streamwater chemistry varies across ... Lowe and co-authors ... Washington, the Cary Institute of Ecosystem Studies, the University of ... 664 water samples collected every 10 meters along 32 tributaries ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... April 30, 2012 It is often thought that starting ... they try to set a good example for their children. ... children into the home may affect parents, eating habits. ... a child,s eating preferences may influence how a family eats. ...
... Efforts to prevent obesity among low-income infants should focus not ... reasons behind unhealthy feeding practices, according to a study to ... (PAS) annual meeting in Boston. Adding cereal to bottles ... Academy of Pediatrics because it may lead to overfeeding and ...
... Calif. Avocado, a significant fruit crop grown in ... threatened by Phytophthora root rot (PRR), a disease that ... in Latin America and crippled production in Australia and ... estimated to cost avocado growers approximately $30-40 million a ...
Cached Biology News:Starting a family does not encourage parents to eat healthier 2Low-income moms under stress may overfeed infants 2New avocado rootstocks are high-performing and disease-tolerant 2New avocado rootstocks are high-performing and disease-tolerant 3
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
ANTI ALPHA FSH:B...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
MOUSE ANTI BOVINE TROPONIN I...
Biology Products: